Biogen | BIIB - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
AbbVie USD 3.63B 54M 2026-06
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
ALKERMES USD 196.64M 67.96M 2026-06
Amgen USD 1.72B 134M 2026-06
Bayer EUR 3.96B 267M 2026-06
Biogen USD 709.7M 155.4M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
Incyte USD 351.73M 23.64M 2026-06
Merck USD 2.89B 219M 2026-06
Moderna USD 216M 43M 2026-06
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06
Pfizer USD 3.41B 496M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.63B 307M 2026-06
Sanofi EUR 2.49B 252M 2026-03
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Teva Pharmaceutical Industries USD 1.03B 34M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
United Therapeutics USD 206.7M 50.1M 2026-06
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06